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Abstract
Background
We examine the clinical significance and biomarkers of tissue plasminogen activator (tPA)-
catalyzed clot lysis time (CLT) in patients with intermediate-risk pulmonary embolism (PE).
Methods
Platelet-poor, citrated plasma was obtained from patients with PE. Healthy age- and sex-
matched patients served as disease-negative controls. Fibrinogen, α2-antiplasmin, plasmin-
ogen, thrombin activatable fibrinolysis inhibitor (TAFI), plasminogen activator Inhibitor 1
(PAI-1), thrombin time and D-dimer were quantified. Clotting was induced using CaCl2, tis-
sue factor, and phospholipid. Lysis was induced using 60 ng/mL tPA. Time to 50% clot lysis
(CLT) was assessed by both thromboelastography (TEG) and turbidimetry (A405).
Results
Compared with disease-negative controls, patients with PE exhibited significantly longer
mean CLT on TEG (+2,580 seconds, 95% CI 1,380 to 3,720 sec). Patients with PE and a
short CLT who were treated with tenecteplase had increased risk of bleeding, whereas
those with long CLT had significantly worse exercise tolerance and psychometric testing for
quality of life at 3 months. A multivariate stepwise removal regression model selected PAI-1
and TAFI as predictive biomarkers of CLT.
Conclusion
The CLT from TEG predicted increased risk of bleeding and clinical failure with tenecteplase
treatment for intermediate-risk PE. Plasmatic PAI-1 and TAFI were independent predictors
of CLT.
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Introduction
Clinical trials have suggested that treating intermediate-risk, acute PE patients with fibrinoly-
tics reduces hemodynamic complications but at a cost of increased bleeding risk [1–3]. In four
meta-analyses by Chatterjee et al. Nakamura et al., Marti et al., and Riera-Maestre et al. the
rates of major bleeding with fibrinolytic treatment for PE were 9.2%, 6.6%, 9.9%, and 5.9%
respectively. Intracranial bleeding rates were 1.5%, 1.7%, 1.7%, and 1.7% respectively [4–7].
Experimental data in animals [8] and humans [9, 10] demonstrate that the bleeding rate
increases with increasing dose of fibrinolytic agent. Recent work has been hypothesis generat-
ing in the use of half-dose tPA to reduce right ventricular dysfunction after PE compared with
no fibrinolysis, while potentially decreasing the bleeding risk associated with full-dose tPA
[11–13]. It can be hypothesized that the dose of plasminogen activator for PE should be tai-
lored to patient phenotype including clot size, patient body weight, age, and gender, as well as
circulating proteins that determine the degree of plasmatic resistance to tPA fibrinolysis. Our
objectives were first to examine the frequency of plasmatic resistance to tPA in patients with
intermediate-risk PE, and then to determine which plasma proteins have independent predic-
tive value for determining susceptibility to tPA-catalyzed clot lysis. The overarching intent is to
identify a biomarker, or biomarker panel, to predict the risk of hemorrhage or poor clinical
response with standard dose fibrinolytics. To accomplish this, we used two commonly used
methods for assessing clot lysis time (CLT): turbidimetry and thromboelastography (TEG) on
plasma samples from patients with intermediate-risk PE [1]. We then assessed the predictive-
ness of CLT and correlated biomarkers on known hemorrhagic and clot-related, clinical
outcomes.
Methods
Study design
Plasma from the primary study group was obtained from a prospective, multicenter trial for
treatment of intermediate-risk pulmonary embolism (TOPCOAT), clinical trials identifier:
NCT00680628 [1]. Carolinas HealthCare System Institutional Review Board approved the
original study (IRB #01-08-01A) and this study had prospective ethical approval. The methods
for TOPCOAT are detailed in a separate publication [14]. Patients were randomized to receive
a bolus infusion of the plasminogen activator tenecteplase (TNKase1) or volume-matched
0.9% NaCl placebo. To provide disease-negative control data, we used plasma from patients
who were matched to TOPCOAT by age and sex from apparently healthy individuals who
were tested for acute PE, but had no clinical evidence of PE within 90 days. To provide positive
control data, we used plasma from patients with conditions known to produce hypofibrinolysis
via different mechanisms, including patients with diabetes mellitus type II, and patients with
metabolic syndrome [15, 16]. All patients in this study provided written informed consent.
Blood was obtained prior to treatment from an arm vein, either by venipuncture or withdrawal
from an indwelling venous catheter, into a vacuum tube containing sodium citrate (BD Vacu-
tainer1, 2.7 mL, 0.109 Molar/3.2% sodium citrate). Phlebotomy in TOPCOAT patients was
performed prior to administration of study drug. Blood was immediately placed on ice, and
centrifuged within 30 minutes at 4°C at 3,000 x g for 20 minutes, which has been shown to
deplete platelets [17]. Plasma was immediately aliquoted and frozen at -80°C.
Analysis of Clot Lysis Time
We used two methods to assess clot lysis time (CLT) to mimic two distinct in-vivo physiologi-
cal conditions. First, to represent CLT in stagnant (zero shear) conditions, we measured
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turbidity using light transmittance (SpectraMax, Molecular Devices; Sunnyvale, CA). Second,
to measure CLT under shear conditions, we assessed loss of mechanical stiffness, using TEG
(Haemoscope 5000; Braintree, MA). For both assays, plasma comprised 50% of the total mix-
ture volume. Turbidity was measured at 405nm at 37°C [18]. Coagulation was initiated by
inducing clotting with calcium chloride at a final concentration of 15 mM, human tissue factor
at a final concentration of 0.6 pM (Dade Innovin; Siemens, USA), and phospholipids, DOPC:
DOPS (7:3, w/w), at a final concentration of 12 μM (Avanti Polar Lipids; Alabaster, Al) [18–
20]. To induce fibrinolysis, tissue plasminogen activator (tPA) (Alteplase, Genentech; San
Francisco, CA) was immediately added to the plasma prior to clot formation at a final concen-
tration of 60 ng/mL. Tris-buffered saline (50 mM Tris-HCl, 0.1 M NaCl, pH 7.4) was used as a
buffering agent. Calcium chloride, tissue factor, phospholipid mixture, tPA, and buffer were
mixed in disposable TEG cups containing heparinase (Haemonetics Corporation; Braintree,
MA) prior to addition of plasma. Following mixing of reagents, human plasma was added to
start the reaction. 100 μL of volume was transferred from the TEG cup to a 96 well plate in
duplicate, and allowed to run on the spectrophotometer at 23°C. The remaining reaction vol-
ume was run using TEG. The CLT is derived from a clot-lysis profile and defined as the time
between the midpoint of the rise to maximum turbidity or shear stress during coagulation,
to the midpoint of the return back to baseline turbidity or shear stress during clot lysis
(S1A–S1D Fig).
Measurement of plasma proteins
All plasma proteins with the exception of PAI-1 were measured on the STA Compact coagula-
tion analyzer1 (Diagnostica Stago; Parsippany, NJ) with reagents purchased from the manu-
facturer and analyzed as follows: Fibrinogen concentration (mg/dL) was determined using the
Clauss clotting method (STA Fibrinogen 5), α2-antiplasmin, plasminogen and thrombin acti-
vatable fibrinolysis inhibitor (TAFI) concentrations were determined via chromogenic assays
(STA Stachrom α2-antiplasmin, STA Stachrom plasminogen and STA Stachrom TAFI values
expressed as a percent relative to the standard control). All assays were performed with the use
of a commercial calibration standard; D-dimer concentrations (μg/mL) were measured using a
latex agglutination assay (STA Liatest D-DI). Plasminogen activator Inhibitor 1 (PAI-1,
pg/mL) was quantified with a commercial ELISA assay (Life Technologies, Grand Island, NY).
The Life Sciences Human PAI-1 kit is a solid phase sandwich Enzyme Linked-Immuno-Sor-
bent Assay (ELISA). A monoclonal antibody specific for Hu PAI-1 has been coated onto the
wells of the microtiter strips provided. The assay used in this study measures total PAI-1.
Clinical outcomes
To assess the association of CLT with clinical outcomes from the TOPCOAT sample, we
grouped patients according to CLT value. First, we assessed the area under the receiver operat-
ing characteristic curve, as well as the significance of a short CLT (below the 1st quartile for dis-
ease-negative patients) on risk of major or clinically relevant non-major bleeding. Bleeding was
defined as major if it was clinically overt and associated with a decrease in hemoglobin level of
2.0 g/dL; if bleeding led to the transfusion of2 units of red cells; or if bleeding was intracra-
nial or retroperitoneal, occurred in another critical site, or contributed to death [21]. Non-
major clinically relevant bleeding was defined as overt bleeding that did not meet the criteria
for major bleeding but was associated with medical intervention drug, or discomfort or
impairment of activities of daily life. Second, we assessed the association of a prolonged
CLT (CLT> 95th percentile from the disease-negative group) with five efficacy outcomes
assessed at three months post treatment: 1. Baseline pulse oximetry, 2. Quality of life related to
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post-thrombotic syndrome as measured by the validated VEINES QoL survey [22] 3. Percep-
tion of physical and mental wellness from the RAND Standard Form 36 (SF 36) [23] 4.
Six-minute walk distance (m), [24] and 5. The proportion of patients with evidence of right
ventricular dysfunction or overload on echocardiography, defined as RV dilation (>43 mm
transverse diameter in diastole), RV hypokinesis, or an estimated RV systolic pressure
>45 mmHg.
Statistical analysis
Samples were evaluated for normality using the Shapiro-Wilk test. Means were compared
using analysis of variance with Dunnett’s post-hoc test to determine significance with pairwise
comparisons of test groups (PE, diabetes mellitus and metabolic syndrome) versus control
with p< 0.05 considered significant. To determine which variables explain the change in CLT
in the PE samples, we performed multivariate linear regression with age, BMI, fibrinogen, D-
dimer, plasminogen, α2-antiplasmin, thrombin time, TAFI and PAI-1 as independent variables
and CLT from turbidimetry or TEG as the dependent variable using two separate equations.
The stepwise removal process was then used to select significant independent variables. Data
were analyzed using SPSS (Version 22; IBM, Armonk NY). Graphs were produced using Sig-
maPlot (version 12.0; Systat, San Jose, CA).
Results
Table 1 compares clinical features between the three control groups and the experimental
group: normal (n = 20, negative control), metabolic syndrome (n = 10, positive control), diabe-
tes mellitus (n = 10, positive control), and intermediate-risk PE patients from TOPCOAT. Of
these patients (n = 76 total), 36 were treated with tenecteplase, and 40 treated with placebo).
All TOPCOAT patients received either full-dose unfractionated heparin (n = 34), low molecu-
lar weight heparin (n = 49), or both (n = 10) prior to blood draw. The four groups were similar
Table 1. Comparison of clinical data and plasma proteins between patient groups.
Variable Control
(n = 20)
Diabetes Mellitus
(n = 10)
Metabolic Syndrome
(n = 10)
TOPCOAT (Intermediate-risk PE)
(n = 76)
Age 56.5 ± 14.6 57.8 ± 14.2 65.1 ± 20 55 ± 13.9
Male gender (%) 11 (55%) 5 (50%) 7 (70%) 46 (61%)
Body mass index (kg/m2) 27.9 ± 8.1 31.3 ± 5.7 34.7 ± 4.8* 33.1 ± 9.1*
Diabetes Mellitus 0 10 0 10
Prior venous
thromboembolism
0 0 0 17
Active malignancy 0 0 0 15
Thrombin time (s) 18.1 ± 2 19.6 ± 1.2 19.8 ± 1.7 61 ± 47.1*
Fibrinogen (mg/dL) 320.9 ± 54.7 350.7 ± 52 338 ± 70.7 412.5 ± 148.9*
α2-antiplasmin† 102.7 ± 12.3 103.2 ± 5.7 106.4 ± 6.7 99.2 ± 18.2
Plasminogen† 98.2 ± 16 102.3 ± 11.3 104.5 ± 13.7 109.8 ± 27.2
TAFI† 107.3 ± 16.9 104.3 ± 18.6 106.9 ± 18.7 99.5 ± 25.7
D-dimer (μg/mL) 0.447 ± 0.429 0.360 ± 0.141 0.429 ± 0.307 6.592 ± 5.102*
PAI-1 (pg/mL) 1072.3 ± 780.1 3457 ± 2518.7* 4171.3 ± 2177.7* 2367.5 ± 2212.9*
*p < 0.05 from one-way ANOVA with Dunnett’s comparison with control
†Units are expressed as percent activity when compared to standardized controls provided by the manufacturer (Stago Diagnostica). Abbreviations: TAFI-
thrombin activatable ﬁbrinolysis inhibitor; PAI-plasminogen activator inhibitor. Values are listed as mean ± SD unless otherwise indicated.
doi:10.1371/journal.pone.0148747.t001
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in age, but patients with metabolic syndrome and TOPCOAT group had a higher body mass
index (p< 0.05). Table 1 also compares relative concentrations and activities of biomarkers rel-
evant to fibrinolysis in the three control groups and PE patients. As expected, D-dimer and
fibrinogen concentrations were elevated in patients with PE, and thrombin times were pro-
longed from heparin treatment. PAI-1 was significantly increased in both the positive control
groups and the PE group when compared with disease-negative controls. The mean plasma
antigenic content of α2-antiplasmin, plasminogen, or TAFI were not different between groups.
Fig 1 and Table 2 show the CLTs measured with both turbidimetry and TEG (S1A–S1D Fig
in the online supplement demonstrates the methodology for turbidimetry, and S2A and S2B
Fig shows the regression curves and Bland Altman plots, respectively comparing the CLT
results from each method). As measured by TEG, the mean CLT was significantly prolonged
for patients with PE, diabetes mellitus and metabolic syndrome compared with controls
Fig 1. Dot plot of clot lysis time values for each patient.Horizontal lines represent the mean of each group. Abbreviations: Cont-apparently healthy
control patients; TEG-thromboelastography; MtSyn- metabolic syndrome; DM-diabetes mellitus; Spec-spectrophotometry (turbidimetric method);
TOP-TOPCOAT. *p < 0.05 vs. control, **p < 0.01 vs. control, ANOVA with Dunnett’s post-hoc.
doi:10.1371/journal.pone.0148747.g001
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(p = 0.03, p = 0.0026, and p = 0.0005, respectively). A significantly higher proportion of
patients with PE (18%) had a CLT> 10,800 seconds compared with controls (0%) (95% confi-
dence interval for the difference in 18% = 0.3 to 27%). Using the turbidimetric technique, the
mean CLT was not significantly prolonged for patients with PE compared with disease-nega-
tive controls, but was prolonged in patients with diabetes mellitus and metabolic syndrome
compared with controls (p = 0.623, p = 0.002 and p = 0.003, respectively).
To determine significance of CLT on patients with major bleeding, we first tested if CLT
(measured via TEG) predicted hemorrhage associated with tenecteplase treatment using
receiver operating curve analysis. Of the 36 patients with PE who received tenecteplase, one
had major hemorrhage (fatal intracranial hemorrhage), one had severe hemorrhage that did
not meet the study definition of major hemorrhage (vaginal bleeding associated with hypoten-
sion and red cell transfusion, but no drop in hemoglobin), and six others that met the defini-
tion of clinically relevant non-major bleeding. Average age and BMI of these eight patients
were 61.4 and 30.9, respectively, and all patients with hemorrhage had met criteria for TOP-
COAT enrollment. The CLT was significantly lower in the eight patients with hemorrhage
(3,823 ± 1,456 seconds) versus 28 patients without hemorrhage (6,761 ± 4,321 seconds,
p = 0.005 unpaired t-test). The diagnostic accuracy of CLT from TEG in predicting major or
clinically significant bleeding was moderate with an area under the ROC of 0.711 (95%
CI = 0.526 to 0.892). The odds ratio for hemorrhage for patients with CLT< 1st quartile of
TOPCOAT patients (3,780 seconds) was 11.6 (95% CI = 1.6–104), and both patients with
major or near major hemorrhage had a CLT below 3,780 seconds. Table 3 compares the mean
values for five outcomes at three months for patients with a prolonged CLT (i.e.,> 95 percen-
tile for healthy controls or> 6,869 seconds) and found significantly lower VEINEs QoL, physi-
cal component of the SF-36 and the six-minute walk distance values in patients treated with
tenecteplase. Additionally, we assessed the percentage of patients with right ventricular (RV)
dysfunction or overload at 3 months. Of the 36 patients treated with tenectaplase, there were
12 patients with prolonged CLT. For those treated with tenecteplase, RV dysfunction or
Table 2. Clot lysis times (seconds) from thromboelastography and turbidimetry.
Value Healthy
Control
(Spec)
Diabetes
Mellitus
(Spec)
Obese
Metabolic
Syndrome
(Spec)
TOPCOAT
(Spec)
Total
Sample
(Spec)
Healthy
Control
(TEG)
Diabetes
Mellitus
(TEG)
Obese
Metabolic
Syndrome
(TEG)
TOPCOAT
(TEG)
Total
Sample
(TEG)
Valid
data (N)
20 10 10 76 116 20 10 10 76 116
Mean 4,898 7,243* 11,296* 5,014 5,369 4,741 10,529* 11,296* 7,319* 7,494
SD 920 1,907 4,914 1,657 1,770 1,029 4,561 4,914 4,735 4,659
Upper
quartile
5,319 9,303 8,465 6,284 6,574 5,440 15,145 15,145 12,449 12,449
Median 4,685 7,308 7,235 4,628 5,018 4,703 11,225 14,925 5,095 5,363
Lower
quartile
4,441 5,364 6,088 3,739 4,085 3,842 5,728 6,039 3,780 4,081
Centile
95
7,145 9,280 9,935 8,344 9,181 6,869 15,145 15,145 15,145 15,145
Centile
10
3,465 4,830 3,765 2,735 2,957 3,013 4,595 4,285 2,613 2,633
*p < 0.05 from one-way ANOVA with Dunnett’s comparison with control
Abbreviations: Spec-spectrophotometry (turbidimetric method); TEG-Thromboelastography; TOPCOAT-tenecteplase or placebo: cardiopulmonary
outcomes at three months; SD-Standard deviation.
doi:10.1371/journal.pone.0148747.t002
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overload was found in 36% with prolonged CLT, versus 26% with normal CLT (95% CI for dif-
ference, -20.6 to 42.4%, exact two-sided p = 0.46), and for placebo, RV dysfunction or overload
was found in 54% with prolonged CLT, versus 27% with normal CLT (95% CI for difference of
17% = -5.1 to 55.4%, exact two-sided p = 0.095).
We then sought to determine which biomarkers correlated to CLT using multivariate linear
regression for each technique, using data from all 116 patients (TOPCOAT + normal + meta-
bolic syndrome + diabetes mellitus). Table 4 presents the β coefficients and p values for each
variable entered. Examination of the β coefficients and associated p values suggest PAI-1 as the
most robust predictor of CLT in both the turbidimetry and TEG methods. For the turbidimetry
regression model, stepwise variable removal retained biomarkers D-dimer, PAI-1 and α2-anti-
plasmin, yielding a best-fit prediction model with F (3, 113) = 36.3, p< 0.001, that explained
Table 3. Clinical outcomes three months after pulmonary embolism based upon clot lysis time at diagnosis.
Clinical parameter Tenecteplase,
normal CLT
Tenecteplase,
prolonged CLT*
P‡ Placebo, normal
CLT
Placebo,
prolonged CLT*
P‡
Resting pulse oximetry value (%) 97.0 ± 1.4 96.5 ± 1.8 0.400 97.0 ± 1.7 97.0 ± 1.3 0.931
Lowest recorded pulse oximetry value (%) 92.9 ± 5.5 86.3 ± 14.3 0.057 93.1 ± 3.6 92.6 ± 4.3 0.704
VEINEs QoL score** 96.4 ± 10.5 85.9 ± 12.1 0.013 86.5 ± 19.4 93.5 ± 13.4 0.263
Physical component of the SF-36**
(Normalized values at 3 month follow up)
49.8 ± 7.9 42.0 ± 10.3 0.019 41.2 ± 12.8 41.5 ± 14.1 0.952
Mental component of the SF-36
(Normalized values at 3 month follow up)
52.6 ± 8.1 54.1 ± 11.6 0.674 51.6 ± 12.3 55.2 ± 4.7 0.323
Six-minute walk distance (feet at 3 month
follow-up)
1472.9 ± 261.1 1094.1 ± 328.6 0.002 1338.0 ± 423.5 1350.4 ± 318.4 0.931
Values are listed as Mean±SD
Abbreviations: CLT-clot lysis time; OoL-quality of life
*Prolonged CLT deﬁned as > 95th percentile using thromboelastography.
**Increasing values indicate better quality of life.
‡Unpaired t-test, comparing patients with normal CLT to patients with prolonged CLT.
doi:10.1371/journal.pone.0148747.t003
Table 4. β coefficients and P values for independent variables of multivariate linear regression*.
Turbidimetry Thromboelastography
Component Beta coefﬁcient P value Beta coefﬁcient P value
Intercept b0 = 1,279.8 P = 0.31 b0 = -3,232.5 P = 0.261
Age b1 = 5.107 P = 0.556 b1 = 0.55 P = 0.978
BMI b2 = 12.94 P = 0.388 b2 = 40.18 P = 0.241
Fibrinogen b3 = 0.639 P = 0.6 b3 = 0.74 P = 0.79
D-Dimer b4 = -61.07 P = 0.031 b4 = 37.46 P = 0.558
Plasminogen b5 = 1.56 P = 0.836 b5 = -2.70 P = 0.876
α2-antiplasmin b6 = 15.67 P = 0.108 b6 = 31.34 P = 0.158
Thrombin time b7 = -2.59 P = 0.415 b7 = -9.14 P = 0.208
TAFI b8 = 5.94 P = 0.373 b8 = 25.65 P = 0.093
PAI-1 b9 = 0.49 P < 0.001 b9 = 1.62 P < 0.001
df = 115, F = 12.24 P < 0.001, Ra2 = 46.8% df = 115, F = 20.218 P < 0.001, Ra2 = 60.1%
*Clot lysis time was the dependent variable as measured by either turbidimetry or thromboelastography, yielding two different equations
Abbreviations: TAFI-thrombin activatable ﬁbrinolysis inhibitor; PAI-plasminogen activator inhibitor; BMI-body mass index.
doi:10.1371/journal.pone.0148747.t004
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49.3% of the variance of CLT by turbidimetry (r2 = 0.493). For the TEG regression model, step-
wise variable removal retained biomarkers PAI-1 and TAFI, yielding a significant best-fit pre-
diction model, F (3, 113) = 61.2, p< 0.001, that explained 62.1% of the variance of CLT by
TEG (r2 = 0.621). Neither equation produced clinically useful prediction for hemorrhage or the
outcomes in Table 3.
Discussion
We report the novel finding that the in-vitro CLT predicts risk of hemorrhage and clinical
response to plasminogen activator treatment for intermediate-risk PE. Patients with PE and a
short TEG CLT who were treated with tenecteplase had an increased risk of hemorrhage, and
patients with a prolonged TEG CLT had less benefit in terms of quality of life and exercise tol-
erance at three months. The TEG technique of assessing CLT appeared better suited at
unmasking underlying resistance to lysis than the turbidimetric technique using light spectros-
copy. For example, 18% of PE patients had a marked resistance to lysis, evidenced by a TEG
CLT> 180 min (10,800 seconds), and the longest CLT from turbidimetry was 9,975 seconds.
In multivariate analysis, the PAI-1 and TAFI protein concentrations were the most robust
explanatory variables for a prolonged CLT with both techniques.
These findings have relevance in clinical settings where providers have administered a plas-
minogen-activating agent to patients with acute, intermediate-risk PE and subsequent compli-
cations of severe hemorrhage developed. Indeed, recent meta-analyses further do not support
the use of thrombolytics in hemodynamically stable patients with acute PE [4–7]. These
adverse outcomes increase the risk of morbidity and mortality, may lengthen hospital length of
stay, and confound clinical decisions on appropriateness of fibrinolytic treatment of intermedi-
ate-risk PE. Thus, a biomarker to optimize the therapeutic index by personalizing the dose of
plasminogen activating enzyme to the patient’s plasmatic resistance profile offers the potential
to bridge current knowledge gaps in identifying which patients with intermediate-risk PE may
be the best candidates for fibrinolytic therapy.
Our CLT and biomarker findings add to prior work showing that unrestrained fibrinolysis
predicts hemorrhage risk and impaired fibrinolysis worsens treatment efficacy for VTE. Lobo
et al., demonstrated elevated D-dimer levels, ostensibly a biomarker of hyperfibrinolysis, were
associated with an increased rate of major bleeding [25]. In this registry study, 3 of the 8
patients with major or near major hemorrhages following tenecteplase treatment had elevated
D-dimer levels in the fourth quartile. Conversely, prior work has established that hypofibrino-
lysis increases the risk of primary and recurrent venous thromboembolism. [26–32] This effect
may contribute to a reduced long-term therapeutic effect of plasminogen activators, assuming
that VTE recurrence worsens quality of life. In the current study, we demonstrate for the first
time, to our knowledge, that a substantial percentage of patients with PE have a markedly pro-
longed TEG CLT at the time of treatment (and prior to the initiation of any fibrinolytics).
A variety of plasma-based clot lysis assays have been used to access CLT, including those
using human thrombin together with tPA [33, 34], as well as those based on serial measure-
ments of D-dimer release [35, 36]. The advantage of these methods to determine CLT is
thought to derive overall plasma fibrinolytic capacity by representing the integrated effect of
both procoagulant and profibrinolytic factors. The technique of turbidimetry (A405) under
non-shear conditions has been used extensively in the past to assess global efficiency of lysis.
The addition of an automated method to produce shear stress while measuring tPA-catalyzed
CLT in plasma has only recently been described [37, 38].
To provide rigorous assessment, we measured CLT in all subjects using two methods. Over-
all, we found these two methods demonstrate good correlation and agreement in healthy
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subjects and also both identify a prolonged CLT in patients with metabolic syndrome and dia-
betes mellitus. Nevertheless, TEG was superior in identifying patients with intermediate-risk
PE who exhibited a prolonged CLT (36.8% using TEGmethod versus 10% using the turbidime-
try method). This implies a notable difference when measuring CLT under shear versus non-
shear conditions for patients diagnosed with intermediate-risk PE and suggests that TEG may
be a more sensitive technique for identifying abnormal CLT in these (and potentially other)
patients. While we had no prior assumption that one method would be superior to the other,
we postulate based on our findings that the mechanical action of TEG more closely mimics the
in-vivo flow dynamics surrounding a pulmonary thrombus. With both methods, we corrected
for the anticoagulant effect of therapeutic heparin, by adding excess lyophilized heparinase
(sufficient to overcome 6IU/mL) prior to measurement of CLT. Additionally, we used Alte-
plase over Tenecteplase because Alteplase has FDA clearance to treat PE, and remains more
widely available than Tenecteplase. Although Tenecteplase has a lower rate of PAI-1 inhibition
than Alteplase (1.5x105 M-1sec-1 versus 1.5x107 M-1sec-1) the rate of PAI-1 neutralization is the
primary determinant of the net catalytic activity in-vivo for Tenecteplase owing to its decreased
clearance by the liver via the mannose receptor [39, 40]. The inhibitory action of TAFI affects
plasmin binding to fibrin and is therefore independent of the plasminogen activator structure.
For these reasons, we believe that PAI-1 and TAFI will remain accurate biomarkers of hemor-
rhage risk for patients treated with Alteplase or Tenecteplase. It is unclear at this point how-
ever, if screening plasmatic levels of PAI-1 and TAFI in hemodynamically stable patients with
acute PE will move the benefit balance in favor of thrombolysis.
We observed that, 18.4% (n = 14) of patients from the TOPCOAT group, 50% (n = 5) of the
metabolic syndrome group, and 40% (n = 4) of the diabetes mellitus group demonstrated
increasing tensile clot strength over time. We hypothesize that this may be the result of tPA-
induced release of fibrinopeptides A and B from fibrinogen that binds and protects soluble
thrombin from inhibition, further perpetuating a pro-coagulant state [41, 42]. However, the
concentration of tPA used in our experiments was much lower than that used in the prior
experiments examining fibrinopeptide release.
Limitations include the fact that these data have no radiological evidence from TOPCOAT
that definitively show evidence of resistance of pulmonary emboli to fibrinolysis. In addition to
the number of samples being limited by the small number of patients with this pathology who
met inclusion criteria in the original study, ten plasma samples from the original TOPCOAT
trial were not analyzed due to: inability to draw blood (n = 1), patient withdrawal (n = 2), sam-
ple loss or no follow-up (n = 7). This small sampling of patients certainly limits the conclusions
we may draw, but nonetheless maintains the work as hypothesis generating. Due to limited
patient plasma supply, the TEG samples were run in singlet. The PAI-1 assay only measured
total protein, as opposed to active enzyme, and it is possible that measurements of active
enzyme could increase the importance of PAI-1 in the multivariate model. TOPCOAT samples
had higher average BMI when compared to healthy controls (p = 0.041), a relevant point in
view of a multivariate analysis that found obesity as the strongest predictor of quality of life in
the TOPCOAT patients [43]. In the present work, analysis of variance, conducted to examine
pairwise comparisons of BMI categories (overweight, obese, morbidly obese) with CLT by
either turbidimetry or TEG, yielded no significant pattern of difference that would justify BMI
as a confounding variable in CLT.
In conclusion, we found that the CLT is a highly variable phenotype that predicts the thera-
peutic index of fibrinolysis for intermediate-risk PE. The primary mediators of CLT are the
plasma proteins PAI-1 and TAFI.
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